Anti-tumour necrosis factor (TNF)-a agents have been increasingly used to treat patients affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory disorders. However, the widening use of biologics is related to a new class of adverse events called paradoxical reactions. Its pathogenesis remains unclear, but it is suggested that cytokine remodulation in predisposed individuals can lead to the inflammatory process. Here, we dissect the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-a therapies.
Lopetuso, L. R., Cuomo, C., Mignini, I., Gasbarrini, A., Papa, A., Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, N/A; 24 (9): 8187-N/A. [doi:10.3390/ijms24098187] [https://hdl.handle.net/10807/240212]
Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases
Lopetuso, Loris Riccardo;Mignini, Irene;Gasbarrini, Antonio;Papa, Alfredo
2023
Abstract
Anti-tumour necrosis factor (TNF)-a agents have been increasingly used to treat patients affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory disorders. However, the widening use of biologics is related to a new class of adverse events called paradoxical reactions. Its pathogenesis remains unclear, but it is suggested that cytokine remodulation in predisposed individuals can lead to the inflammatory process. Here, we dissect the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-a therapies.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
